rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2025-146-157rsp-3724Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESУвеит при спондилоартрите: современные возможности противовоспалительной терапииUveitis in spondyloarthritis: current possibilities of anti-inflammatory therapyhttps://orcid.org/0000-0002-5493-6045ГодзенкоА. А.GodzenkoA. A.

Годзенко Алла Александровна

125993, Москва, ул. Баррикадная, 2/1, стр. 1,

115522, Москва, Каширское шоссе, 34а

Alla A. Godzenko

125993, Moscow, Barrikadnaya str., 2/1, building 1,

115522, Moscow, Kashirskoye Highway, 34A 

alla1106@mail.ruhttps://orcid.org/0000-0003-4597-4987ШереметН. Л.SheremetN. L.

119021, г. Москва, ул. Россолимо, 11

Natalia L. Sheremet

119021, Moscow, Rossolimo str., 11

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34а

Evgeny L. Nasonov

115522, Moscow, Kashirskoye Highway, 34A 

ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России; ФГБНУ «Научно- исследовательский институт ревматологии им. В.А. Насоновой»РоссияRussian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation; V.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт глазных болезней им. М.М. Краснова»РоссияM.M. Krasnov Research Institute of Eye DiseasesRussian FederationФГБНУ «Научно- исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202501052025632146157Copyright © Годзенко А.А., Шеремет Н.Л., Насонов Е.Л., 20252025Годзенко А.А., Шеремет Н.Л., Насонов Е.Л.Godzenko A.A., Sheremet N.L., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3724

Увеит – частое внескелетное проявление (ВП) анкилозирующего спондилита (АС) и других спондилоартритов (СпА). Рецидивирующее течение увеита при СпА способствует развитию осложнений, влияющих на зрение. Своевременное лечение обострения увеита и предотвращение рецидивов являются важными компонентами ведения больных СпА. В статье обсуждаются подходы к современной противовоспалительной терапии увеита при СпА, включая применение традиционных и таргетных препаратов. Представлены данные клинических исследований по влиянию различных схем лечения на течение увеита при СпА, а также сравнительная оценка эффективности генно-инженерных биологических и таргетных синтетических препаратов.

Uveitis is a common extra-skeletal manifestation of ankylosing spondylitis (AS) and other spondyloarthritis (SpA). The recurrent course of uveitis in SpA contributes to the development of complications affecting vision. Timely treatment of uveitis exacerbation and prevention of relapses is an important component of SpA management. The article discusses approaches to modern anti-inflammatory therapy of uveitis in SрA, including traditional and targeted drugs. The data from clinical studies on the effect of various treatment regimens on the course of uveitis in SpA are presented, as well as a comparative assessment of the effectiveness of biologic and targeted synthetic drugs.

увеитспондилоартритгенно-инженерные биологические препаратытаргетные синтетические препаратыuveitisspondyloarthritisbiologicstargeted synthetic drugsReferencesУвеиты неинфекционные: клинические рекомендации ООО «Ассоциация врачей-офтальмологов», ООО «Общество офтальмологов России». 2024. URL: https://cr.minzdrav.gov.ru/ (Accessed: 12 July 2024).Non-infectious uveitis: Clinical guidelines of the Association of Ophthalmologists, Society of Ophthalmologists of Russia. 2024 (In Russ.). URL: https://cr.minzdrav.gov.ru/ (Accessed: 12 July 2024).Tsirouki T, Dastiridou A, Symeonidis C, Tounakaki O, Brazitikou I, Ocul Immunol Inflamm. 2018;26(1):2-16. doi: 10.1080/09273948.2016.1196713Tsirouki T, Dastiridou A, Symeonidis C, Tounakaki O, Brazitikou I, Ocul Immunol Inflamm. 2018;26(1):2-16. doi: 10.1080/09273948.2016.1196713Standardization of Uveitis Nomenclature (SUN) Working Group. Development of classification criteria for the uveitides. Am J Ophthalmol. 2021;228:96-105. doi: 10.1016/j.ajo.2021.03.061Standardization of Uveitis Nomenclature (SUN) Working Group. Development of classification criteria for the uveitides. Am J Ophthalmol. 2021;228:96-105. doi: 10.1016/j.ajo.2021.03.061Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021;80(12):1511-1521. doi: 10.1136/annrheumdis-2021-221035Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021;80(12):1511-1521. doi: 10.1136/annrheumdis-2021-221035Gordon H, Burisch J, Ellul P, Karmiris K, Katsanos K, Allocca M, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2024;18(1):1-37. doi: 10.1093/ecco-jcc/jjad108Gordon H, Burisch J, Ellul P, Karmiris K, Katsanos K, Allocca M, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2024;18(1):1-37. doi: 10.1093/ecco-jcc/jjad108Sharma SM, Jackson D. Uveitis and spondyloarthropathies. Best Pract Res Clin Rheumatol. 2017;31(6):846-862. doi: 10.1016/j.berh.2018.08.002Sharma SM, Jackson D. Uveitis and spondyloarthropathies. Best Pract Res Clin Rheumatol. 2017;31(6):846-862. doi: 10.1016/j.berh.2018.08.002D’Ambrosio EM, La Cava M, Tortorella P, Gharbiya M, Campanella M, Iannetti L. Clinical features and complications of the HLA-B27-associated acute anterior uveitis: A metanalysis. Semin Ophthalmol. 2017;32(6):689-701. doi: 10.3109/08820538.2016.1170158D’Ambrosio EM, La Cava M, Tortorella P, Gharbiya M, Campanella M, Iannetti L. Clinical features and complications of the HLA-B27-associated acute anterior uveitis: A metanalysis. Semin Ophthalmol. 2017;32(6):689-701. doi: 0.3109/08820538.2016.1170158Bernal-Morales C, Ramanan AV, Pavesio C. Use of immunomodulators in non-infectious uveitis: Lights and shadows. Eye (Lond). 2024;38(17):3231-3242. doi: 10.1038/s41433-024-03294-9Bernal-Morales C, Ramanan AV, Pavesio C. Use of immunomodulators in non-infectious uveitis: Lights and shadows. Eye (Lond). 2024;38(17):3231-3242. doi: 10.1038/s41433-024-03294-9Подряднова МВ, Балабанова РМ, Урумова ММ, Эрдес ШФ. Взаимосвязь клинических характеристик анкилозирующего спондилита с трудоспособностью и производительностью труда. Научно-практическая ревматология. 2014;52(5):513-519. doi: 10.14412/1995-4484-2014-513-519Podryadnova MV, Balabanova RM, Urumova MM, Erdes ShF. Correlation between clinical characteristics of ankylosing spondylitis and work capacity and productivity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(5):513-519 (In Russ.). doi: 10.14412/1995-4484-2014-513-519Морозов ВИ. Гемато-офтальмический барьер: структурнофункциональные особенности. Российский офтальмологический журнал. 2017;10(4):68-72. doi: 10.21516/2072-0076-2017-10-4-68-72Morozov VI. A hematoophthalmic barrier: Structural and functional features. Russian Ophthalmological Journal. 2017;10(4):68-72 (In Russ.). doi: 10.21516/2072-0076-2017-10-4-68-72Fiorelli VM, Bhat P, Foster CS. Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm. 2010;18(2):116-120. doi: 10.3109/09273941003587558Fiorelli VM, Bhat P, Foster CS. Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm. 2010;18(2):116-120. doi: 10.3109/09273941003587558Muñoz-Fernández S, Hidalgo V, Fernández-Melón J, Schlincker A, Bonilla G, Ruiz-Sancho D, et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol. 2003;30(6):1277-1279.Muñoz-Fernández S, Hidalgo V, Fernández-Melón J, Schlincker A, Bonilla G, Ruiz-Sancho D, et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol. 2003;30(6):1277-1279.Benitez-del-Castillo JM, Garcia-Sanchez J, Iradier T, Bañares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond). 2000;14(Pt 3A):340-343. doi: 10.1038/eye.2000.84Benitez-del-Castillo JM, Garcia-Sanchez J, Iradier T, Bañares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond). 2000;14(Pt 3A):340-343. doi: 10.1038/eye.2000.84Годзенко АА, Бочкова АГ, Румянцева ОА, Разумова ИЮ, Бадокин ВВ, Эрдес Ш. Влияние сульфасалазина на течение увеита у больных анкилозирующим спондилитом. Научнопрактическая ревматология. 2016;54(Прил 1):33-37. doi: 10.14412/1995-4484-2016-1S-33-37Godzenko AA, Bochkova AG, Rumyantseva OA, Razumova IYu, Badokin VV, Erdes ShF. Course of uveitis in patients with ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(Suppl 1):33-37 (In Russ.). doi: 10.14412/1995-4484-2016-1S-33-37Zu Hoerste MM, Walscheid K, Tappeiner C, Zurek-Imhoff B, Heinz C, Heiligenhaus A. The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: Results from a retrospective cohort study. Graefes Arch Clin Exp Ophthalmol. 2018;256(10):1985-1992. doi: 10.1007/s00417-018-4082-xZu Hoerste MM, Walscheid K, Tappeiner C, Zurek-Imhoff B, Heinz C, Heiligenhaus A. The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: Results from a retrospective cohort study. Graefes Arch Clin Exp Ophthalmol. 2018;256(10):1985-1992. doi: 10.1007/s00417-018-4082-xBouzid N, Jamilloux Y, Chapurlat R, Pradat P, De Parisot A, Kodjikian L, et al. Impact of systemic treatments on the course of HLA-B27-associated uveitis: A retrospective study of 101 patients. PLoS One. 2020;15(3):e0230560. doi: 10.1371/journal.pone.0230560Bouzid N, Jamilloux Y, Chapurlat R, Pradat P, De Parisot A, Kodjikian L, et al. Impact of systemic treatments on the course of HLA-B27-associated uveitis: A retrospective study of 101 patients. PLoS One. 2020;15(3):e0230560. doi: 10.1371/journal.pone.0230560Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77(6):808-818. doi: 10.1136/annrheumdis-2018-213225Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77(6):808-818. doi: 10.1136/annrheumdis-2018-213225Kaçmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117(3):576-584. doi: 10.1016/j.ophtha.2009.08.010Kaçmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117(3):576-584. doi: 10.1016/j.ophtha.2009.08.010Poizeau F, Leducq S, Fardet L, Beylot-Barry M, Chaby G, Chastagner M, et al.; Psoriasis Research Group (GRPso) and the Centre of Evidence of the French Society of Dermatology. Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithm. Ann Dermatol Venereol. 2024;151(3):103287. doi: 10.1016/j.annder.2024.103287Poizeau F, Leducq S, Fardet L, Beylot-Barry M, Chaby G, Chastagner M, et al.; Psoriasis Research Group (GRPso) and the Centre of Evidence of the French Society of Dermatology. Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithm. Ann Dermatol Venereol. 2024;151(3):103287. doi: 10.1016/j.annder.2024.103287Гайдукова ИЗ, Ребров АП, Лапшина СА, Оттева ЭН, Дубинина ТВ, Бадокин ВВ, и др. Применение нестероидных противовоспалительных препаратов и генно-инженерных биологических препаратов для лечения аксиальных спондилоартритов. Рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2017;55(5):474-484. doi: 10.14412/1995-4484-2017-474-484Gaidukova IZ, Rebrov AP, Lapshina SA, Otteva EN, Dubinina TV, Badokin VV, et al. Use of nonsteroidal anti-inflammatory drugs and biological agents for the treatment of axial spondyloarthritides. Recommendations of the Spondyloarthritis Study Group of Experts, All-Russian Public Organization «The Association of Rheumatology of Russia». Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(5):474-484 (In Russ.). doi: 10.14412/1995-4484-2017-474-484Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19-34. doi: 10.1136/ard-2022-223296Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19-34. doi: 10.1136/ard-2022-223296Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R Jr, Brézin AP, Chee SP, et al.; Fundamentals of Care for Uveitis International Consensus Group. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology. 2018;125(5):757-773. doi: 10.1016/j.ophtha.2017.11.017Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R Jr, Brézin AP, Chee SP, et al.; Fundamentals of Care for Uveitis International Consensus Group. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology. 2018;125(5):757-773. doi: 10.1016/j.ophtha.2017.11.017Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52(8):2447-2451. doi: 10.1002/art.21197Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52(8):2447-2451. doi: 10.1002/art.21197Rudwaleit M, Rødevand E, Holck P, Vanhoof J, Kron M, Kary S, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study. Ann Rheum Dis. 2009;68(5):696- 701. doi: 10.1136/ard.2008.092585Rudwaleit M, Rødevand E, Holck P, Vanhoof J, Kron M, Kary S, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study. Ann Rheum Dis. 2009;68(5):696- 701. doi: 10.1136/ard.2008.092585van Denderen JC, Visman IM, Nurmohamed MT, SuttorpSchulten MS, van der Horst-Bruinsma IE. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. J Rheumatol. 2014;41(9):1843-1848. doi: 10.3899/jrheum.131289van Denderen JC, Visman IM, Nurmohamed MT, SuttorpSchulten MS, van der Horst-Bruinsma IE. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. J Rheumatol. 2014;41(9):1843-1848. doi: 10.3899/jrheum.131289Lee JT, Yates WB, Rogers S, Wakefield D, McCluskey P, Lim LL. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. Br J Ophthalmol. 2018;102(12):1672-1678. doi: 10.1136/bjophthalmol-2017-311234Lee JT, Yates WB, Rogers S, Wakefield D, McCluskey P, Lim LL. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. Br J Ophthalmol. 2018;102(12):1672-1678. doi: 10.1136/bjophthalmol-2017-311234Calvo-Río V, Blanco R, Santos-Gómez M, Rubio-Romero E, Cordero-Coma M, Gallego-Flores A, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum. 2016;46(1):95-101. doi: 10.1016/j.semarthrit.2016.03.002Calvo-Río V, Blanco R, Santos-Gómez M, Rubio-Romero E, Cordero-Coma M, Gallego-Flores A, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum. 2016;46(1):95-101. doi: 10.1016/j.semarthrit.2016.03.002Yazgan S, Celik U, Işık M, Yeşil NK, Baki AE, Şahin H, et al. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis. Int Ophthalmol. 2017;37(1):139-145. doi: 10.1007/s10792-016-0239-yYazgan S, Celik U, Işık M, Yeşil NK, Baki AE, Şahin H, et al. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis. Int Ophthalmol. 2017;37(1):139-145. doi: 10.1007/s10792-016-0239-yvan Bentum RE, Heslinga SC, Nurmohamed MT, Gerards AH, Griep EN, Koehorst CBJM, et al. Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab – The GO-EASY Study. J Rheumatol. 2019;46(2):153-159. doi: 10.3899/jrheum.180312van Bentum RE, Heslinga SC, Nurmohamed MT, Gerards AH, Griep EN, Koehorst CBJM, et al. Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab – The GO-EASY Study. J Rheumatol. 2019;46(2):153-159. doi: 10.3899/jrheum.180312Rudwaleit M, Rosenbaum JT, Landewé R, Marzo-Ortega H, Sieper J, van der Heijde D, et al. Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. Arthritis Care Res (Hoboken). 2016;68(6):838-844. doi: 10.1002/acr.22848Rudwaleit M, Rosenbaum JT, Landewé R, Marzo-Ortega H, Sieper J, van der Heijde D, et al. Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. Arthritis Care Res (Hoboken). 2016;68(6):838-844. doi: 10.1002/acr.22848van der Horst-Bruinsma I, van Bentum R, Verbraak FD, Rath T, Rosenbaum JT, Misterska-Skora M, et al. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW. RMD Open. 2020;6(1):e001161. doi: 10.1136/rmdopen-2019-001161van der Horst-Bruinsma I, van Bentum R, Verbraak FD, Rath T, Rosenbaum JT, Misterska-Skora M, et al. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW. RMD Open. 2020;6(1):e001161. doi: 10.1136/rmdopen-2019-001161van der Horst-Bruinsma IE, van Bentum RE, Verbraak FD, Deodhar A, Rath T, Hoepken B, et al. Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: Final 2-year results from the multicenter phase IV C-VIEW study. Ther Adv Musculoskelet Dis. 2021;13:1759720X211003803. doi: 10.1177/1759720X211003803van der Horst-Bruinsma IE, van Bentum RE, Verbraak FD, Deodhar A, Rath T, Hoepken B, et al. Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: Final 2-year results from the multicenter phase IV C-VIEW study. Ther Adv Musculoskelet Dis. 2021;13:1759720X211003803. doi: 10.1177/1759720X211003803Martín-Varillas JL, Sanchez-Bilbao L, Calvo-Río V, Adán A, Hernanz I, Gallego-Flores A, et al. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: Multicentre study of 80 patients. RMD Open. 2022;8(2):e002693. doi: 10.1136/rmdopen-2022-002693Martín-Varillas JL, Sanchez-Bilbao L, Calvo-Río V, Adán A, Hernanz I, Gallego-Flores A, et al. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: Multicentre study of 80 patients. RMD Open. 2022;8(2):e002693. doi: 10.1136/rmdopen-2022-002693Deschenes J, Murray PI, Rao NA, Nussenblatt RB; International Uveitis Study Group. International Uveitis Study Group (IUSG): Clinical classification of uveitis. Ocul Immunol Inflamm. 2008;16(1):1-2. doi: 10.1080/09273940801899822Deschenes J, Murray PI, Rao NA, Nussenblatt RB; International Uveitis Study Group. International Uveitis Study Group (IUSG): Clinical classification of uveitis. Ocul Immunol Inflamm. 2008;16(1):1-2. doi: 10.1080/09273940801899822Rosenbaum JT. Effect of etanercept on iritis in patients with ankylosing spondylitis. Arthritis Rheum. 2004;50(11):3736-3737. doi: 10.1002/art.20754Rosenbaum JT. Effect of etanercept on iritis in patients with ankylosing spondylitis. Arthritis Rheum. 2004;50(11):3736-3737. doi: 10.1002/art.20754Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al.; Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230-3236. doi: 10.1002/art.11325Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al.; Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230-3236. doi: 10.1002/art.11325Sieper J, Koenig A, Baumgartner S, Wishneski C, Foehl J, Vlahos B, et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis. 2010;69(1):226-229. doi: 10.1136/ard.2008.103192Sieper J, Koenig A, Baumgartner S, Wishneski C, Foehl J, Vlahos B, et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis. 2010;69(1):226-229. doi: 10.1136/ard.2008.103192Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol. 2003;87(7):925. doi: 10.1136/bjo.87.7.925Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol. 2003;87(7):925. doi: 10.1136/bjo.87.7.925Cobo-Ibáñez T, del Carmen Ordóñez M, Muñoz-Fernández S, Madero-Prado R, Martín-Mola E. Do TNF-blockers reduce or induce uveitis? Rheumatology (Oxford). 2008;47(5):731-732. doi: 10.1093/rheumatology/ken091Cobo-Ibáñez T, del Carmen Ordóñez M, Muñoz-Fernández S, Madero-Prado R, Martín-Mola E. Do TNF-blockers reduce or induce uveitis? Rheumatology (Oxford). 2008;47(5):731-732. doi: 10.1093/rheumatology/ken091Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56(10):3248-3252. doi: 10.1002/art.22918Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56(10):3248-3252. doi: 10.1002/art.22918Raffeiner B, Ometto F, Bernardi L, Botsios C, Punzi L. Inefficacy or paradoxical effect? Uveitis in ankylosing spondylitis treated with etanercept. Case Rep Med. 2014;2014:471319. doi: 10.1155/2014/471319Raffeiner B, Ometto F, Bernardi L, Botsios C, Punzi L. Inefficacy or paradoxical effect? Uveitis in ankylosing spondylitis treated with etanercept. Case Rep Med. 2014;2014:471319. doi: 10.1155/2014/471319Kwon HY, Kim YJ, Kim TH, Ahn SJ. Comparison of incidence or recurrence of anterior uveitis in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors. J Clin Med. 2024;13(3):912. doi: 10.3390/jcm13030912Kwon HY, Kim YJ, Kim TH, Ahn SJ. Comparison of incidence or recurrence of anterior uveitis in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors. J Clin Med. 2024;13(3):912. doi: 10.3390/jcm13030912Насонов ЕЛ. Новые возможности фармакотерапии иммуновоспалительных ревматических заболеваний: фокус на ингибиторы интерлейкина 17. Научно-практическая ревматология. 2017;55(1):68-86. doi: 10.14412/1995-4484-2017-68-86Nasonov EL. New possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases: A focus on inhibitors of interleukin-17. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(1):68-86 (In Russ.). doi: 10.14412/1995-4484-2017-68-86Насонов ЕЛ, Коротаева ТВ, Дубинина ТВ, Лила АМ. Ингибиторы ИЛ23/ИЛ17 при иммуновоспалительных ревматических заболеваниях: новые горизонты. Научно-практическая ревматология. 2019;55(4):400-406. doi: 10.14412/1995-4484-2019-400-406Nasonov EL, Korotaeva TV, Dubinina TV, Lila AM. IL-23/IL-17 inhibitors in immunoinflammatory rheumatic diseases: New horizons. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(4):400-406 (In Russ.). doi: 10.14412/1995-4484-2019-400-406Дубинина ТВ, Гайдукова ИЗ, Саблева НА, Сапожников КВ, Соколова ВД, Толкачева ДГ. Сравнительная оценка клинико-экономической эффективности ингибиторов интерлейкина 17 при лечении анкилозирующего спондилита. Научнопрактическая ревматология. 2022;60(6):594-601. doi: 10.47360/1995-4484-2022-594-601Dubinina TV, Gaydukova IZ, Sableva NА, Sapozhnikov KV, Sokolova VD, Tolkacheva DG. Comparative pharmacoeconomic effectiveness of interleukin-17 inhibitors for the treatment of ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(6):594-601 (In Russ.). doi: 10.47360/1995-4484-2022-594-601Ruiz de Morales JMG, Puig L, Daudén E, Cañete JD, Pablos JL, Martín AO, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmun Rev. 2020;19(1):102429. doi: 10.1016/j.autrev.2019.102429Ruiz de Morales JMG, Puig L, Daudén E, Cañete JD, Pablos JL, Martín AO, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmun Rev. 2020;19(1):102429. doi: 10.1016/j.autrev.2019.102429How Shing Koy E, Labauge P, Baillet A, Prati C, Marotte H, Pers YM. Immunomodulation with IL-17 and TNF-α in spondyloarthritis: Focus on the eye and the central nervous system. Ther Adv Musculoskelet Dis. 2021;13:1759720X211025894. doi: 10.1177/1759720X211025894How Shing Koy E, Labauge P, Baillet A, Prati C, Marotte H, Pers YM. Immunomodulation with IL-17 and TNF-α in spondyloarthritis: Focus on the eye and the central nervous system. Ther Adv Musculoskelet Dis. 2021;13:1759720X211025894. doi: 10.1177/1759720X211025894Jacquot R, Kodjikianc L, Chapurlat R, Sèvea P. Targeted therapies for uveitis in spondyloarthritis: A narrative review. Joint Bone Spine. 2024;(91):105697. doi: 10.1016/j.jbspin.2024.105697Jacquot R, Kodjikianc L, Chapurlat R, Sèvea P. Targeted therapies for uveitis in spondyloarthritis: A narrative review. Joint Bone Spine. 2024;(91):105697. doi: 10.1016/j.jbspin.2024.105697Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, a fully human antibody to interleukin17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72. doi: 10.1126/scitranslmed.3001107Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, a fully human antibody to interleukin17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72. doi: 10.1126/scitranslmed.3001107Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL; AIN457A2208 Study Group. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122(5):939-948. doi: 10.1016/j.ophtha.2014.12.033Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL; AIN457A2208 Study Group. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122(5):939-948. doi: 10.1016/j.ophtha.2014.12.033Deodhar AA, Miceli-Richard C, Baraliakos X, Marzo-Ortega H, Gladman DD, Blanco R, et al. Incidence of uveitis in secukinumab-treated patients with ankylosing spondylitis: Pooled data analysis from three phase 3 studies. ACR Open Rheumatol. 2020;2(5):294-299. doi: 10.1002/acr2.11139Deodhar AA, Miceli-Richard C, Baraliakos X, Marzo-Ortega H, Gladman DD, Blanco R, et al. Incidence of uveitis in secukinumab-treated patients with ankylosing spondylitis: Pooled data analysis from three phase 3 studies. ACR Open Rheumatol. 2020;2(5):294-299. doi: 10.1002/acr2.11139Deodhar A, Poddubnyy D, Rahman P, Ermann J, Tomita T, Bolce R, et al. Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program. J Rheumatol. 2023;50(8):1020-1028. doi: 10.3899/jrheum.221022Deodhar A, Poddubnyy D, Rahman P, Ermann J, Tomita T, Bolce R, et al. Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program. J Rheumatol. 2023;50(8):1020-1028. doi: 10.3899/jrheum.221022Мазуров ВИ, Эрдес ШФ, Гайдукова ИЗ, Дубинина ТВ, Пристром АМ, Кундер ЕВ, и др. Долгосрочная эффективность и безопасность нетакимаба у пациентов с активным анкилозирующим спондилитом: результаты трех лет применения в рамках международного многоцентрового рандомизированного двойного слепого клинического исследования III фазы BCD-085-5/ASTERA. Современная ревматология. 2024;18(1):35-46. doi: 10.14412/1996-7012-2020-4-39-49Mazurov VI, Erdes SF, Gaydukova IZ, Dubinina TV, Pristrom AM, Kunder EV, et al. Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA. Modern Rheumatology Journal. 2020;14(4):39 49 (In Russ.). doi: 10.14412/1996-7012-2020-4-39-49Годзенко АА, Агафонова ЕМ, Димитрева АЕ, Разумова ИЮ, Урумова ММ. Течение увеита у пациентов с анкилозирующим спондилитом на фоне терапии ингибиторами интерлейкина 17. Научно-практическая ревматология. 2023;61(5):590-595. doi: 10.47360/1995-4484-2023-590-595Godzenko AA, Agafonova EM, Dimitreva AE, Razumova IYu, Urumova MM. Course of uveitis in patients with ankylosing spondylitis during the interleukin 17 inhibitors therapy. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(5):590- 595 (In Russ.). doi: 10.47360/1995-4484-2023-590-595Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, et al. Tofacitinib for the treatment of ankylosing spondylitis: A phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80(8):1004-1013. doi: 10.1136/annrheumdis-2020-219601Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, et al. Tofacitinib for the treatment of ankylosing spondylitis: A phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80(8):1004-1013. doi: 10.1136/annrheumdis-2020-219601Deodhar A, van der Heijde D, Sieper J, van den Bosch F, Maksymowych WP, Kim TH, et al. Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: One-year results of a doubleblind, placebo-controlled study and open-label extension. Arthritis Rheumatol. 2022;74(1):70-80. doi: 10.1002/art.41911Deodhar A, van der Heijde D, Sieper J, van den Bosch F, Maksymowych WP, Kim TH, et al. Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: One-year results of a doubleblind, placebo-controlled study and open-label extension. Arthritis Rheumatol. 2022;74(1):70-80. doi: 10.1002/art.41911van der Heijde D, Deodhar A, Maksymowych WP, Sieper J, van den Bosch F, Kim TH, et al. Upadacitinib in active ankylosing spondylitis: Results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. RMD Open. 2022;8(2):e002280. doi: 10.1136/rmdopen-2022-002280van der Heijde D, Deodhar A, Maksymowych WP, Sieper J, van den Bosch F, Kim TH, et al. Upadacitinib in active ankylosing spondylitis: Results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. RMD Open. 2022;8(2):e002280. doi: 10.1136/rmdopen-2022-002280Baraliakos X, van der Heijde D, Sieper J, Inman RD, Kameda H, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the openlabel extension of the SELECT-AXIS 2 study. Arthritis Res Ther. 2024;26(1):197. doi: 10.1186/s13075-024-03412-8Baraliakos X, van der Heijde D, Sieper J, Inman RD, Kameda H, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the openlabel extension of the SELECT-AXIS 2 study. Arthritis Res Ther. 2024;26(1):197. doi: 10.1186/s13075-024-03412-8Vitale A, Palacios-Olid J, Caggiano V, Ragab G, Hernández-Rodríguez J, Pelegrín L, et al. Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: A prospective cohort study from the international AIDA network registries. Front Med (Lausanne). 2024;11:1439338. doi: 10.3389/fmed.2024.1439338Vitale A, Palacios-Olid J, Caggiano V, Ragab G, Hernández-Rodríguez J, Pelegrín L, et al. Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: A prospective cohort study from the international AIDA network registries. Front Med (Lausanne). 2024;11:1439338. doi: 10.3389/fmed.2024.1439338Kraev K, Uchikov P, Hristov B, Kraeva M, Basheva-Kraeva Y, Popova-Belova S, et al. Coexistence of ankylosing spondylitis and Behçet’s disease: Successful treatment with upadacitinib. Immun Inflamm Dis. 2024;12(4):e1242. doi: 10.1002/iid3.1242Kraev K, Uchikov P, Hristov B, Kraeva M, Basheva-Kraeva Y, Popova-Belova S, et al. Coexistence of ankylosing spondylitis and Behçet’s disease: Successful treatment with upadacitinib. Immun Inflamm Dis. 2024;12(4):e1242. doi: 10.1002/iid3.1242Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: A retrospective study. Ann Rheum Dis. 2006;65(12):1631-1634. doi: 10.1136/ard.2006.052092Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: A retrospective study. Ann Rheum Dis. 2006;65(12):1631-1634. doi: 10.1136/ard.2006.052092Lie E, Lindström U, Zverkova-Sandström T, Olsen IC, Forsbladd’Elia H, Askling J, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: Results from the Swedish biologics register. Ann Rheum Dis. 2017;76(9):1515-1521. doi: 10.1136/annrheumdis-2016-210931Lie E, Lindström U, Zverkova-Sandström T, Olsen IC, Forsbladd’Elia H, Askling J, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: Results from the Swedish biologics register. Ann Rheum Dis. 2017;76(9):1515-1521. doi: 10.1136/annrheumdis-2016-210931Wendling D, Joshi A, Reilly P, Jalundhwala YJ, Mittal M, Bao Y. Comparing the risk of developing uveitis in patients initiating antitumor necrosis factor therapy for ankylosing spondylitis: An analysis of a large US claims database. Curr Med Res Opin. 2014;30(12):2515-2521. doi: 10.1185/03007995.2014.969368Wendling D, Joshi A, Reilly P, Jalundhwala YJ, Mittal M, Bao Y. Comparing the risk of developing uveitis in patients initiating antitumor necrosis factor therapy for ankylosing spondylitis: An analysis of a large US claims database. Curr Med Res Opin. 2014;30(12):2515-2521. doi: 10.1185/03007995.2014.969368Khoury G, Morel J, Combe B, Lukas C. Occurrence of anterior uveitis in patients with spondyloarthritis treated with tumor necrosis factor inhibitors: Comparing the soluble receptor to monoclonal antibodies in a large observational cohort. Arthritis Res Ther. 2020;22(1):94. doi: 10.1186/s13075-020-02187-yKhoury G, Morel J, Combe B, Lukas C. Occurrence of anterior uveitis in patients with spondyloarthritis treated with tumor necrosis factor inhibitors: Comparing the soluble receptor to monoclonal antibodies in a large observational cohort. Arthritis Res Ther. 2020;22(1):94. doi: 10.1186/s13075-020-02187-yLindström U, Bengtsson K, Olofsson T, Di Giuseppe D, Glintborg B, Forsblad-d’Elia H, et al. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: Does the choice of biological therapy matter? Ann Rheum Dis. 2021;80(11):1445-1452. doi: 10.1136/annrheumdis-2021-220420Lindström U, Bengtsson K, Olofsson T, Di Giuseppe D, Glintborg B, Forsblad-d’Elia H, et al. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: Does the choice of biological therapy matter? Ann Rheum Dis. 2021;80(11):1445-1452. doi: 10.1136/annrheumdis-2021-220420Roche D, Badard M, Boyer L, Lafforgue P, Pham T. Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: A systematic review, a pairwise and network meta-analysis of randomized controlled trials. Arthritis Res Ther. 2021;23(1):192. doi: 10.1186/s13075-021-02549-0Roche D, Badard M, Boyer L, Lafforgue P, Pham T. Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: A systematic review, a pairwise and network meta-analysis of randomized controlled trials. Arthritis Res Ther. 2021;23(1):192. doi: 10.1186/s13075-021-02549-0Bechman K, Yang Z, Adas M, Nagra D, S Uğuzlar A, Russell MD, et al. Incidence of uveitis in patients with axial spondylarthritis treated with biologics or targeted synthetics: A systematic review and network meta-analysis. Arthritis Rheumatol. 2024;76(5):704-714. doi: 10.1002/art.42788Bechman K, Yang Z, Adas M, Nagra D, S Uğuzlar A, Russell MD, et al. Incidence of uveitis in patients with axial spondylarthritis treated with biologics or targeted synthetics: A systematic review and network meta-analysis. Arthritis Rheumatol. 2024;76(5):704-714. doi: 10.1002/art.42788

The authors declare that there are no conflicts of interest present.